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Familial Adult Myoclonic Epilepsy (FAME) is a genetically heterogeneous disorder char-
acterized by cortical tremor and seizures. Intronic TTTTA/TTTCA repeat expansions in
SAMD12 (FAME1) are the main cause of FAME in Asia. Using genome sequencing and
repeat-primed PCR, we identify another site of this repeat expansion, inMARCH6 (FAME3) in
four European families. Analysis of single DNA molecules with nanopore sequencing and
molecular combing show that expansions range from 3.3 to 14 kb on average. However, we
observe considerable variability in expansion length and structure, supporting the existence
of multiple expansion configurations in blood cells and fibroblasts of the same individual.
Moreover, the largest expansions are associated with micro-rearrangements occurring near
the expansion in 20% of cells. This study provides further evidence that FAME is caused by
intronic TTTTA/TTTCA expansions in distinct genes and reveals that expansions exhibit an
unexpectedly high somatic instability that can ultimately result in genomic rearrangements.
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FAME is an autosomal dominant, very slowly progressivecondition characterized by cortical tremor affecting mainlythe hands, frequently associated with generalized myoclonic
and sometimes tonic-clonic seizures, and, more rarely, focal sei-
zures1–3. This condition was first described in Japan as benign
adult familial myoclonic epilepsy (BAFME), and subsequently
also referred to as familial cortical myoclonic tremor with epi-
lepsy (FCMTE) or autosomal dominant cortical myoclonus and
epilepsy (ADCME). Several different chromosome loci, identified
through linkage, at 2p11-2q11, 3q26-q28, 5p15, and 8q24, have
been reported4–7 but the genetic variants underlying the disorder
have remained elusive for 20 years despite extensive sequencing
of genes contained in these intervals.
Recently, intronic expansions composed of mixed TTTTA/
TTTCA repeats in SAMD12 on chromosome (chr) 8q24 have
been identified as the main cause of FAME1 (BAFME1) in the
Japanese and Chinese populations8–11. SAMD12 pentanucleotide
repeat expansions are associated with a specific haplotype origi-
nating from a founder effect in Asia8,10. Interestingly, two Japa-
nese families without SAMD12 expansion had similar TTTTA/
TTTCA repeat expansions in RAPGEF2 (chr4) and TNRC6A
(chr16)8.
We previously investigated a large French family with FAME3
(previously referred as FCMTE3, OMIM 613608) linked to a 9.31
Mb region on chr 5p15.31-p15.16,12 (Family 1; Fig. 1a).
Sequencing of all exons in the linked interval by next generation
sequencing had excluded the existence of pathogenic coding
variants. Parallel research in a large Dutch FAME pedigree
(Family 3; Fig. 1c) linked to the same region on chr5p had
revealed a missense variant (NM_001332.3:c.3130G>A, p.
Glu1044Lys) in CTNND2, which segregated in all affected family
members but one, who was considered a possible phenocopy13,14.
In the present study, we present evidence that FAME3 results
from repeat expansions similar to those described in SAMD12 for
FAME1 families, but located at a different site in the first intron
of MARCH6. These expansions range from 3 to 14 kb on average
and show extensive variability in length and structure in blood
cells. This instability extends to genomic micro-rearrangements
occurring at or near the expansion site in individuals with
expansions larger than 10 kb. The mean TTTCA repeat length
inversely correlates with the age at seizure onset, providing fur-
ther evidence that the TTTCA insertion constitutes the patho-
genic part of the expansion. We also demonstrate that expansions
have no detectable consequence on MARCH6 expression in blood
and skin of affected individuals. The observation of similar repeat
expansions in distinct, apparently unrelated genes strongly sug-
gests that these expansions lead to FAME independently of their
genome location and impact on the recipient gene.
Results
Identification of MARCH6 expansions in four families. To
identify the pathogenic variant in Family 1, we performed whole
genome sequencing and, in parallel, sequenced RNA (PolyA+
and small RNA) extracted from lymphoblastic cells of three
affected members and one healthy spouse using short-read Illu-
mina technology (Methods). Combined analysis of genome and
RNA-seq data, including detection of structural variants and
splicing defects, failed to detect any possible pathogenic variants
shared by affected family members or significant alteration of
genes in the linked interval (Supplementary Data 1). We then
used ExpansionHunter15 to search for TTTTA/TTTCA repeat
expansions within the linked region. This analysis revealed reads
with TTTCA repeats mapping to a region composed of 12
TTTTA repeats in the human reference assembly (GRCh37/hg19)
located in intron 1 of MARCH6 (chr5:10,356,460–10,356,519;
Fig. 2a), which was one of the two possible expansion sites pre-
dicted by Ishiura and colleagues8. TTTCA repeats at this locus
were observed in all three affected members of Family 1 but
absent from the healthy spouse and individuals from another
family (Family 5, Supplementary Fig. 2) linked to the FAME2
locus on chr216 (Fig. 2b). Similar results were obtained with
exSTRa17 and STRetch18 while TTTCA repeats were identified in
genomes of both families using TRhist19 (Supplementary Fig. 1).
Visualization of the mapped reads suggested the following
expansion structure: 5ʹ-(TTTTA)exp(TTTCA)exp-3ʹ. To confirm
this result, we set up 5ʹ- and 3ʹ-repeat-primed PCR (RP-PCR)
assays using, respectively, reverse (AAAAT) and forward
(TTTCA) primers directly binding within the expansion (Fig. 2a).
These assays confirmed the existence of 5ʹ-TTTTA and 3ʹ-
TTTCA expanded motifs in all 16 affected individuals tested as
well as in one unaffected individual (Fig. 1a, Fig. 2c, Supplemen-
tary Fig. 3).
We then used the RP-PCR assays to screen the Dutch Family 3
and eleven additional FAME families of European origin
(Fig. 1b–d, Supplementary Fig. 2, Supplementary Data 2) for
the MARCH6 expansion. This analysis revealed expansions in
Family 3 and two additional families (Fig. 1b–d, Supplementary
Fig. 3). The expansion co-segregated with the disorder in all
families, including the affected individual 3-IV-9, who did not
carry the CTNND2 p.Glu1044Lys variant (Fig. 1c, Supplementary
Fig. 3). This finding led to the reclassification of the CTNND2
variant as likely benign, despite its impact on neuronal
morphology in vitro13, and to consider the MARCH6 expansion
as the cause of FAME in this family.
Variability of TTTTA repeat number in control individuals.
Analysis of the region where the expansion occurs in 83 European
control individuals from two different cohorts showed that it
corresponds to a polymorphic microsatellite (short tandem
repeat), with the number of TTTTA repeats typically ranging
from 9 to 20 (Fig. 2a; Supplementary Fig. 4a-b). We never
observed larger TTTTA repeats or repeats containing TTTCA
motifs in control individuals. A similar number of TTTTA
repeats is present in Chimpanzees and Bonobos while this
number is reduced in more distant primate species (Supple-
mentary Fig. 4c).
Haplotype analysis reveals an ancient common ancestor. We
used available SNP data from the French families (Families 1 and
2) to investigate the possibility of a common haplotype under-
lying the expansion. The core haplotype from these two families is
located at chr5(hg19):10301295–10492095, and is only 190.8 kb
(0.35 cM) in size (Supplementary Fig. 5). It encompasses the
entire MARCH6 gene, as well as two other genes (ROPN1L and 5ʹ
of CMBL). We calculated that 253.1 generations (confidence
interval (CI): 76.1–953.6) separate the two families at this locus.
Assuming a 20-year generation span, a common ancestor with
this haplotype would have lived ~5060 years ago (CI:
1520–19080).
Characterization of expansion length and structure. We next
sought to characterize the length and structure of MARCH6
expansions. Since short-read sequencing data do not permit
accurate assessment of repeat number exceeding the corre-
sponding read length, we used long-read Oxford Nanopore
Technology to sequence the genome of six individuals from
Families 1 and 2. Low-coverage sequencing (6–10×) allowed
retrieving one to four reads displaying the expansion per indivi-
dual (Supplementary Fig. 6). Detected expansions typically
spanned 4–6.5 kb and comprised between 791 and 1035 repeats
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in total (Fig. 3a–c, Table 1). However, we observed a substantial
variability in reads covering the expansion in the same individual
(Fig. 3c, d, Supplementary Data 3, a-i). Four reads incompletely
covering the expansion were sequenced in individual 2-IV-9, two
of them spanning a variable TTTCA stretch that was alone up to
5 kb (Supplementary Data 3, j–m).
To confirm that the observed variability possibly reflects
somatic mosaicism and not an artifact introduced by the
sequencing procedure, we used molecular combing (Fiber FISH)
to analyze very long, single-stretched DNA fibers in an unbiased
fashion in blood cells from nine members of Families 1 and 2 and
one healthy control. We stained the TTTCA repeats (in red) and
the regions flanking the expansions (in blue and green) by in situ
hybridization (Fig. 4a), and measured the length of every signal
for all alleles present on at least one coverslip per individual (i.e.,
~100 alleles per coverslip, Supplementary Figs. 7, 8, Supplemen-
tary Table 1). This method confirmed the extensive variability in
expansion length and structure existing in blood cells of each
affected individual (Fig. 4b, c). We recurrently observed staining
patterns compatible with different expansion configurations
(Fig. 4c, d). The existence of multiple expansion configurations
was further supported by positive results using the same RP-PCR
assay with either TTTTA or TTTCA-priming oligos in several
individuals (Supplementary Fig. 9).
Calculation of the size using molecular combing data showed
that expansions range on average from 3.34 to 14.07 kb (Table 1,
Family 1 (F-20)
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Fig. 1 Pedigrees of families withMARCH6 expansions. Pedigrees of Families 1 (a, French), 2 (b, French), 3 (c, Dutch), and 4 (d, German). Individuals with ID
numbers in red are carriers of the expansions. Individuals with ID numbers underlined have been included in whole-genome sequencing analyses.
Individuals with stars have been included in RNA-seq analyses. Black half-filled symbols represent individuals with seizures; Blue symbols indicate
individuals with cortical or myoclonic tremor. Individuals with both cortical tremor and epilepsy appear with one half each. A re-examined carrier individual
presenting with minor signs of tremor (pauci-symptomatic individual) is indicated with a green half square. One male individual of Family 2 had autism
spectrum disorder (yellow corner) and intellectual disability (red corner). Arrows indicate probands. ID numbering in Families 1 and 3 is identical to that
previously described6,14
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Fig. 5a, Supplementary Table 1). The analysis was extended to
fibroblasts of the same individuals from Family 1, with similar
results (Fig. 5b, Supplementary Table 1), suggesting that the
expansions had comparable characteristics in blood and skin.
Micro-rearrangements are associated with large expansions.
The index case of Family 2 (2-IV-9) and his son (2-V-9) exhibited
several DNA molecules harboring complex micro-rearrangements
at the expanded site (Fig. 4e, Supplementary Fig. 10), representing
up to 10% of alleles present on the coverslip (i.e., in up to 20% of
cells, Fig. 4f). Similar micro-rearrangements were observed at a
lower frequency in individuals 1-IV-6, 1-IV-8, 2-IV-18, and 2-V-
22 (Fig. 4f). One of the nanopore reads covering the expansion in
individual 2-IV-9 (read 2-IV-9_ 2, Supplementary Data 3, k)
spanned the 3ʹ flanking region and TTTCA part of the expansion
on chromosome 5p15.2 fused to a region on chromosome Xp22.3
encoding the uncharacterized LOC107985675 ncRNA gene, sug-
gesting that this read corresponds to a micro-rearrangement
involving another chromosome.
The two individuals with frequent micro-rearrangements
strikingly had the largest expansions: the father (2-IV-9) had
expanded alleles ranging from 1.7 to 36.8 kb, with a mean
expansion length of 14.1 kb, while his son had expansions
comprised between 5.4 and 30.1 kb, with an average size of 13.3
kb (Fig. 5a, Table 1, Supplementary Table 1). Micro-
rearrangements thus likely result from somatic instability, and
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Fig. 2 Identification of TTTTA/TTTCA expansions inMARCH6. a Schematic representation of the region where the expansion occurs in intron 1 ofMARCH6
on chromosome 5p15.2. Blue boxes (1–26) representMARCH6 exons. The yellow rectangle indicates the TTTTA repeats while the red rectangle represents
the TTTCA repeats. Yellow (5ʹ-AAAAT assay) and red (3ʹ-TTTCA assay) arrows indicate primers used for the repeat-primed PCR assays while green
arrows schematize the universal primer used in the assay (P3). b Number of TTTTA (actual repeated motif searched for: AAAAT, panel above, yellow) and
TTTCA (actual repeated motif searched for: AAATG, panel below, red) repeats identified by ExpansionHunter from Illumina short-read genome data of
three affected individuals (1-III-16, 1-IV-11, 1-III-20) and one healthy spouse (1-III-14) of Family 1 and another FAME family linked to FAME2 on chr2 (Family
5). Dark and light bars indicate allele 1 and allele 2, respectively. c Results of 5ʹ-AAAAT (left panels) and 3ʹ-TTTCA (right panels) RP-PCR assays in a
control individual (healthy blood donor) and two affected individuals (1-III-16 and 1-IV-11) of Family 1
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Phenotypic variability and genotype–phenotype correlations.
We used data from blood cells to explore further the relationship
between the repeat number of each motif and the age at onset of
epilepsy and tremor. We observed an inverse correlation between
the age at seizure onset and the length of the expansion, mainly
driven by the size of the TTTCA repeats (Fig. 5c). On the con-
trary, no significant correlation was observed between the age at
tremor onset and any parts of the expansion (Fig. 5d).
Accordingly, the two individuals with the largest expansions
(2-IV-9, 2-V-9) were amongst the most severely affected
individuals. Both started to have generalized seizures at 17–18
years of age. Individual 2-IV-9 had a moderate, asymmetric
myoclonic tremor affecting the upper limbs (the right side being
more affected than the left side) when last examined at age 60
years despite treatment with sodium valproate (VPA) and
clobazam (CLB), and he also showed non-specific gait difficulties.
Individual 2-V-9 (28 years old) had autism spectrum disorder
(ASD) and intellectual disability (ID) in addition to FAME and
lived in an institution for disabled persons. Analysis of trio exome
had failed to reveal any other pathogenic variant in this individual
and it remained unclear whether his ASD-ID phenotype was
related to the FAME phenotype.
Conversely, three individuals harboring expansions were
reported asymptomatic at the time of blood sampling (1-IV-8,
1-V-6, 2-V-8) but only two were available for re-examination.
Five years after sampling, at age 30 years, individual 2-V-8 (son of
2-IV-9) had discreet signs of tremor and never had seizures
(Supplementary Fig. 11). This individual was not included in
molecular combing analyses and we could not determine the size
of his expansion. Eleven years after the first sampling, at age 53
years, individual 1-IV-8 reported walking difficulties possibly due















































































































Fig. 3 Characterization of MARCH6 expansions by Nanopore sequencing. a Dot plots comparing two nanopore reads from individual 1-IV-11 displaying the
expansion (Y-axis, scale: 13 kb) with the corresponding hg19 reference region (X-axis, scale: 8.1 kb). The expansions appear as vertical lines. Read 1-IV-11_1
is on the negative strand while read 1-IV-11_2 is on the positive strand. b Analysis of the same raw nanopore reads using NanoSatellite. The signals
corresponding to the expanded repeats appear in blue. c Number of total repeats inferred by NanoSatellite for each extracted read covering the expansion.
Data are displayed for the five individuals for whom reads covering the whole expansion have been detected. Four reads covering parts of the expansion
and flanking regions were obtained for individual 2-IV-9 but are not included in this graph. Dot plots and raw nanopore reads covering completely the
expansion appear in Supplementary Fig. 6 and all sequences are available in Supplementary Data 3. d Schematic representation of the sequence of the
same nanopore reads showing exact TTTTA motifs in yellow and exact TTTCA motifs in red. Gaps between exact repeats possibly correspond to
interruptions or sequencing (base calling) errors
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intermittent photic stimulation. He had a single initially focal,
evolving to bilateral convulsive seizure at age 46 years. He was
treated with a low dose of VPA and had no further seizures.
Neurological examination revealed a mild myoclonic tremor
asymmetrically affecting the left upper limb and the right lower
limb, without any other symptom. This individual had an
expansion of ~5 kb (5.13 kb calculated with Oxford nanopore and
5.06 kb calculated by molecular combing) and a TTTCA length
(2.21 kb) comparable to those of three close relatives (1-IV-6, 1-
IV-9, 1-IV-11), who were all earlier and more severely affected.
This suggests that, although the TTTCA size of the expansion is
on average inversely correlated to the age at seizure onset, the
symptoms at onset, progression and severity of the disorder are
possibly influenced by other factors than the expansion itself or
that the expansion sizes observed in peripheral tissues do not
accurately predict those existing in the brain.
Expansions do not alter MARCH6 expression in blood and
skin. Finally, we investigated whether expansions affect the
expression of MARCH6 in blood cells and fibroblasts of affected
family members. MARCH6 is a ubiquitously expressed gene
encoding an E3 ubiquitin ligase that mediates the degradation of
misfolded or damaged proteins in the endoplasmic reticulum20,21.
At least three isoforms, resulting from alternative splicing of
exons 2–4 have been detected in several tissues, but the full-length
(NM_005885.3) is the predominant isoform (Fig. 6a, GTEx
database).
RNA-seq had previously failed to detect any difference in
MARCH6 expression in lymphoblasts of patients and control
individuals (Supplementary Fig. 12a). Furthermore, no reads
corresponding to MARCH6 mRNA or small RNA with TTTTA
or TTTCA could be detected in these cells (Supplementary
Fig. 12c-d). To confirm these findings, we used real-time qRT-
PCR with four different primer pairs either overlapping exons
7–8 or exons 14–15, or specifically amplifying intron 1 before or
after the expansion. Both exonic assays showed no difference in
MARCH6 RNA levels in total RNA isolated from blood cells (n=
12) or fibroblasts (n= 4) of expansion carriers compared with
non-carrier individuals (n= 10 and 4, respectively; Fig. 6b, c). In
agreement with these results, the MARCH6 protein was present
at similar levels in fibroblasts of expansion carriers and control
individuals (Supplementary Fig. 12b). The intronic assays showed
that RNA molecules containing intron 1 are much less abundant
compared with the spliced transcripts (~30 times lower),
suggesting that these assays detect the transient precursor mRNA.
No difference in the level of intron 1-containing RNAs was
detected in blood cells of expansion carrier versus non-carrier
individuals (Fig. 6d) while a slight decrease was detected in
fibroblasts (Fig. 6e), thus ruling out a massive accumulation of
abnormally spliced MARCH6 mRNA carrying the expansion in
these cells.
Discussion
In this study, we provide evidence that FAME3 is due to TTTTA/
TTTCA repeat expansions in intron 1 ofMARCH6. We show that
these expansions are somatically unstable in blood cells and
fibroblasts, leading to a wide range of expansion sizes and con-
figurations, and that this instability extends to genomic rearran-
gements in individuals with very large (>10 kb) expansions.
Although these genomic rearrangements likely have a deleterious
impact on the corresponding cells, it remains unclear, however,
whether they directly or indirectly contribute to the pathophy-
siology of FAME. We confirmed that there is a significant cor-
relation between the size of the expansion and the age at epilepsy
onset, as previously reported for SAMD12 expansions8, and we
now demonstrate that this correlation is mainly due to the size of
the TTTCA repeats. This finding provides additional evidence
that TTTCA repeats are the pathogenic part of the expansion.
One distinctive feature of individuals with MARCH6 expansions
compared with patients with expansions in other FAME genes is
Table 1 Summarized clinical features and expansion characteristics for 10 affected individuals
Family 1 1 1 1 2 2 2 2 2 2
Patient ID IV-6 IV-8 IV-9 IV-11 IV-9 IV-16 IV-18 V-9 V-20 V-22
Sex M M M F M M F M F M
Age at last examination 58 53 61 60 60 71 67 28 39 44
Clinical features
Age at tremor onset 30 52 25 30 40 14 – NA 14 28
Age at seizure onset 25 46 – 32 18 30 30 17 – 30
Symptom at onset Sz 1 Sz CT CT Sz CT Sz Sz CT Sz/CT
Nanopore sequencing (blood)
No. of P alleles 4 1 1 2 4 1 ND ND ND ND
Mean expansion size 4.73 5.13 4.16 5.67 NA 5.40
Mean 5ʹ-TTTTA size 2.95 2.93 3.08 3.00 NA 4.60
Mean TTTCA size 1.78 2.21 1.08 2.67 >5 0.80
Molecular combing (blood)
No. of P alleles 71 58 25 29 219 ND 50 54 30 38
Mean expansion size 4.62 5.06 3.34 4.92 14.07 5.72 13.33 6.16 7.55
Mean 5ʹ-TTTTA size 0.88 2.33 0.57 1.66 2.37 3.47 1.99 2.81 3.04
Mean TTTCA size 2.82 2.28 2.10 2.86 10.37 1.99 10.04 2.93 3.60
Mean 3ʹ-TTTTA size 0.92 0.46 0.67 0.40 1.32 0.27 1.31 0.41 0.90
Molecular combing (Fibros)
No. of P alleles 10 11 41 13 ND ND ND ND ND ND
Mean expansion size 6.93 4.65 3.82 4.12
Mean 5ʹ-TTTTA size 0.13 1.04 0.02 0.50
Mean TTTCA size 4.56 2.63 2.73 2.04
Mean 3ʹ-TTTTA size 2.24 0.97 1.08 1.59
Ages are expressed in years and expansion size are in kb
CT cortical tremor, F female, M male, P pathogenic, NA not available, ND not done, Sz seizure(s)
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Fig. 4 Somatic mosaicism of MARCH6 expansions detected by molecular combing. a Schematic representation of the molecular code used to stain regions
adjacent to MARCH6 expansions. Probes directed against specific 5ʹ (labeled in blue, B) or 3ʹ (labeled in green, G) flanking regions have been hybridized to
single-stretched DNA fibers extracted from blood cells; TTTCA repeats are stained in red (R). b Representative images seen in a control individual (two
panels on the left) and in nine expansion carrier individuals for whom molecular combing was performed. Y refers to the unstained part between the blue
and red signals; unstained parts detected between the red and green signals or in-between two red signals are referred to as W. c Selected images
observed at the expanded site in the proband of Family 2 (2-IV-9), showing extreme variability of the expansion length and structure in his blood.
d Schematic representation of the different expansion configurations (C1–C6) observed using molecular combing. e) Selected micro-rearrangements
observed at the expanded site in individual 2-IV-9. M (magenta) and C (Cyan) correspond to the overlay of red and blue or green and blue probes,
respectively, indicating an overlap of probes that should normally be separated. All images corresponding to micro-rearrangements observed in individuals
2-IV-9 and 2-V-9 are shown in Supplementary Fig. 10. f Percentage of micro-rearrangements observed in the ten individuals analyzed by molecular
combing. Individuals with the largest expansions (2-IV-9 and 2-V-9) exhibit a higher percentage of rearranged alleles than individuals with smaller
expansions
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Fig. 5 Distribution of expansion lengths and genotype–phenotype correlations. a Box plots showing the distribution of the size of the overall expansion (in
black), as well as the 5ʹ-TTTTA (yellow, Yp–Yn; see Methods for details) and TTTCA (red, R) parts in blood from the nine carrier individuals. Some alleles
showed an unstained part between the red and the green signals, which is referred to as 3ʹ-TTTTA (W, in orange). Box plots elements are defined as
follows: center line: median; box limits: upper and lower quartiles; whiskers: 1.5× interquartile range; points: outliers. b Box plots showing the distribution of
the size of the overall expansion (in black) and each parts: 5ʹ-TTTTA appears in yellow (Yp–Yn; see Methods for details), TTTCA in red (R) in fibroblasts
from four affected individuals of Family 1. c Correlations between the age at seizure onset and the mean size (in kb) of the overall expansion (left), the
TTTCA (middle left), the 5ʹ-TTTTA (middle right), or the overall (5ʹ+ 3ʹ) TTTTA repeats region (right). Individuals with larger TTTCA repeat region have
an earlier age at seizure onset. On the contrary, neither the size of 5ʹ-TTTTA or 5ʹ+ 3ʹ-TTTTA repeats correlate with the age at epilepsy onset. Individuals
included in the graph are 1-IV-6, 1-IV-8, 1-IV-11, 2-IV-9, 2-IV-18, 2-V-9, and 2-V-22. Individuals without epilepsy also have the smallest TTTCA stretches
although they are not included (see Table 1). R2 is the square value of the Pearson coefficient; 95% confidence intervals appear in gray; corresponding R
values and 95% confidence intervals are summarized in Supplementary Table 2. d Correlations between the age at tremor onset and the mean size (in kb)
of the expansion and each part, showing no correlation with any of them. Individuals included in the graph are 1-IV-6, 1-IV-8, 1-IV-9, 1-IV-11, 2-IV-9, 2-V-20,
and 2-V-22
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that seizures precede the onset of tremor in many family
members6,12, but it is unknown whether FAME3 patients have
larger TTTCA repeats than other FAME subtypes.
In a companion study, we describe the identification of iden-
tical expansions in the first intron of STARD7 as the cause of
FAME222. STARD7 encodes a ubiquitous protein involved in
lipid transport and metabolism23. The association of expansions
in apparently unrelated genes with similar phenotypes strongly
suggests that the pathological mechanism is independent from
the gene itself or its function and are more likely related to the
type of expansion.
All FAME-related expansions are located within gene introns,
suggesting that transcription is a key step in the pathogenic
process. Indeed, a common feature of the five genes identified so
far harboring FAME expansions (MARCH6, RAPGEF2, SAMD12,
STARD7, and TNRC6A) is their relatively high expression in the
human brain, although some genes are more specifically expres-
sed in the central nervous system while expression of others is
more ubiquitous. Interestingly, similar intronic TTTTA/TTTCA
expansions in DAB1 have previously been associated with
spinocerebellar ataxia 37 (SCA37)24. The difference in phenotype
might be attributed to the highly specific expression of DAB1 in
the cerebellum, but several genes where FAME expansion occurs
(e.g., MARCH6, STARD7 and TNRC6A) are also highly expressed
in the cerebellum. This suggests that the expression profile of the
gene where the expansion occurs is important but does not suffice
by itself to determine the clinical presentation.
Although MARCH6 is ubiquitously expressed, our results
indicate that the expansion does not alter mRNA and protein
levels in blood cells and fibroblasts of carrier individuals com-
pared with those of non-carrier controls. We could not detect
either an increase in intron 1 retention that would be expected if
RNA molecules containing repeats would accumulate or RNA
foci would form. Furthermore, no reads with TTTTA or TTTCA
repeats corresponding to MARCH6 transcripts were detected in
lymphoblasts of patients. These results contrast with previous
observations made in post-mortem brains of patients with
SAMD12 expansions where reads filled with TTTTA/TTTCA
repeats were detected8, and RNA foci associated with abortive
transcription following SAMD12 expansions were observed8. This
3 p = 0.74
n = 10 n = 12 n = 10 n = 12
n = 10 n = 12 n = 10 n = 12
n = 4 n = 4 n = 4 n = 4




























































































Fig. 6 Expansions do not affect MARCH6 expression in blood or skin. a Schematic representation of the MARCH6 transcript isoforms. The site of the
expansion is indicated by the red box. Arrows indicate primer pairs used to quantifyMARCH6 gene expression. b Results of real-time RT-PCR in blood from
expansion carrier (n= 12) versus healthy (n= 10) individuals with primers specific of exons 7–8 (left) and exons 14–15 (right). c Results of real-time RT-
PCR in fibroblasts from expansion carrier (n= 4) versus unrelated control (n= 4) individuals with primers specific of exons 7–8 (left) and exons 14–15
(right). d Results of real-time RT-PCR in blood from expansion carrier (n= 12) versus healthy (n= 10) individuals with primers located in intron 1 before
(left) or after (right) the expansion. e Results of real-time RT-PCR in fibroblasts from expansion carrier (n= 4) versus unrelated control (n= 4) individuals
with primers located in intron 1 before (left) or after (right) the expansion. Box plots elements are defined as follows: center line: median; box limits: upper
and lower quartiles; whiskers: 1.5× interquartile range; all values are displayed as points; outliers are shown as disconnected points. Statistical comparisons
were done using a Wilcoxon–Mann–Whitney rank-sum test (two-sided)
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discrepancy could be the reflect of processes occurring only in
neuronal cells, although this question clearly needs to be further
addressed, ideally in additional human brain samples or appro-
priate cellular organoid models.
Finally, we showed that FAME3 expansions, like FAME1 and
FAME2 expansions8,22, are associated with a common haplotype.
However, we calculated that this haplotype comes from an
ancestor that would have lived several thousand years ago. It
remains unclear whether the expansion was already present on
the haplotype at that time, as this would assume that it has not
been, or only poorly, counter-selected for more than 200 gen-
erations. Another possibility is that repeats would have expanded
independently from the same predisposing haplotype more
recently. Further investigations are needed to fully understand the
precise mechanisms by which similar pentanucleotide repeat
expansions in different genes occur and lead to FAME.
Methods
FAME families and patients. Families 1 and 2 are seemingly unrelated French
families. Family 1 comprises 24 affected members (16 affected individuals sam-
pled), including 21 with cortical tremor and epilepsy and 3 with cortical tremor
only. The clinical features of this family have previously been reported12. Genome-
wide linkage in this family allowed to identify the FAME3/FCMTE3 locus on
chr5p156. Family 2 comprises 14 affected family members (9 affected individuals
sampled). Clinical data of this family as well as Families 5, 7–11 were briefly
reported25. Clinical data of Family 3, originating from the Netherlands, were
independently reported13,14. Genome-wide linkage in this family was consistent
with linkage to chr5p15 and a CTNND2 missense variant (incompletely) segre-
gating with the disorder was identified13. Family 4 is a previously unreported
German kindred comprising four affected members, two of whom were available
for genetic analyses. The index case, age 54 at the time of the study, suffered from
tremor since age 37 and epileptic seizures since age 41. Epileptic seizures occurred
in his father and grandmother. First seizures of his father occurred at age 40–45
and he also had a rest tremor. In addition, the eldest son of the index case, at the
time of the last follow-up, 32 years old, was affected by tremor since several
months, but no seizures were reported. Updated clinical features of Families 1–4
are summarized in Supplementary Data 2. Informed consents were obtained from
all participants before sampling. Genetic studies were initially approved by local
ethics committee in France (Hôpital Pitié-Salpêtrière, Paris) and Germany (Mar-
burg and Frankfurt hospitals). In the Netherlands, the medical ethical committees
of the Academic Medical Centre (Amsterdam UMC) and the Leiden University
Medical Centre (CME P117/98) approved the study. The overall study was further
approved by the ethics committee of the University Hospital Essen (Germany) in
April 2018.
Whole genome sequencing. One microgram of genomic DNA extracted from
blood samples of eight individuals, three affected individuals (1-III-16, 1-IV-11,
and 1-III-20) and one healthy spouse (1-III-14) of Family 16, as well as three
affected members (5-III-1, 5-III-2, and 5-IV-7) and one healthy spouse (5-III-11)
from the FAME2 (chr2)-linked Family 516, was used to prepare libraries for whole
genome sequencing, using the Illumina TruSeq DNA PCR-Free Library Prepara-
tion Kit, according to the manufacturer’s instructions. After normalization and
quality control, qualified libraries were sequenced on a HiSeqX5 platform from
Illumina (Illumina Inc., CA, USA), as paired-end 150-bp reads. One lane of
HiSeqX5 flow cell was used for each sample, in order to reach an average
sequencing depth of 30X per sample. Sequence quality parameters were assessed
throughout the sequencing run and standard bioinformatics analysis of sequencing
data was based on the Illumina pipeline to generate FASTQ files for each sample.
Reads were then aligned on the human genome (GRCh37) and decoy (Heng Li’s
hs37d5 genome for 1000 genomes project [ftp://ftp.ncbi.nlm.nih.gov/1000gen-
omes/ftp/technical/reference/phase2_reference_assembly_sequence/hs37d5.fa.gz]
was performed using BWA software (mem+default option [https://github.com/
lh3/bwa]). Duplicate sequences were removed from bam files using Sambamba
tools [http://lomereiter.github.io/sambamba/docs/sambamba-view.html]. An
additional realignment step was performed on the bam file using GATK (Realig-
nerTargetCreator/IndelRealigner). Coverage analyses were generated using an in-
house pipeline based on metrics generated by Bedtools programs [http://code.
google.com/p/bedtools/]. Variant calling was performed using four tools: Uni-
fiedGenotyper and HaplotypeCaller from GATK, Platypus [http://www.well.ox.ac.
uk/platypus], and Samtools [http///www.htslib.org/]. Results generated by these
four programs were assembled in a VCF file. Annotation of the VCF file was
carried out and annotated using snpEff and snpSift [http://snpeff.sourceforge.net
and http://snpeff.sourceforge.net/SnpSift.html] based on data available in the
Ensembl [http://www.ensembl.org/index.html] and dbNSFP [https://sites.google.
com/site/jpopgen/dbNSFP] databases.
In an additional step, we screened genome data for tandem repeat expansions
using four different bioinformatics pipelines: ExpansionHunter v2.5.515,
STRetch18, TRhist19, and exSTRa17,26. We also used ExpansionHunter v2.5.5 to
assess the number of TTTTA repeats present in available genome data of 53 control
individuals (Supplementary Fig. 4b). By convention, the repeat motif searched for
is indicated as the first non-redundant repeat motif using alphabetical order of
nucleotides (e.g., AAAAT for TTTTA and AAATG for TTTCA).27
RNA sequencing. In parallel to genome sequencing, RNA-seq and small RNA-seq
was performed for 10 individuals: three affected individuals (1-III-16, 1-IV-9, and
1-IV-11) and one healthy spouse (1-III-24) from Family 1, three affected indivi-
duals (5-III-2, 5-III-3, and 5-IV-4) from Family 5 and three healthy controls
(Ctrl1–3). Total RNA including small RNAs were extracted from immortalized
lymphoblastic cells from each individual using the AllPrepR DNA/RNA/miRNA
kit (Qiagen). RNA-Seq libraries were generated from 600 ng of total RNA using
TruSeq Stranded mRNA Sample Preparation Kit (Part Number RS-122-2101,
Illumina). Polyadenylated RNA (mRNA) were isolated on oligo-d(T) magnetic
beads and fragmented at 94 °C for 2 min with divalent cations. First-strand cDNA
were synthetized from fragmented RNA fragments using a combination of reverse
transcriptase and random primers. Second-strand cDNA synthesis was performed
using DNA Polymerase I and RNase H and replacing dTTP with dUTP. A single
‘A’ base and adapters were successively added on the double-stranded cDNA
products, before purification and amplification using the following conditions: 30 s
at 98 °C; [10 s at 98 °C, 30 s at 60 °C, 30 s at 72 °C] × 12 cycles; 5 min at 72 °C.
Oligos in excess were removed using AMPure XP beads (Beckman Coulter).
Capillary electrophoresis was used to check the quality and estimate the quantity of
final cDNA libraries. Libraries were sequenced on Illumina HiSeq 4000 sequencer
as paired-end 100-base reads following Illumina’s instructions at the GenomEast
platform (IGBMC, Illkirch, France). Image analysis and base calling were per-
formed using RTA 2.7.3 and bcl2fastq 2.17.1.14. Reads were mapped onto the hg38
assembly of Homo sapiens genome using TopHat228,29 version 2.0.14 and Bowtie
version 2-2.1.030. Reads mapping to rRNA and Spikes were discarded. Gene
expression was quantified using HTSeq-0.6.1 [http://www-huber.embl.de/users/
anders/HTSeq/doc/overview.html] with gene annotations from Ensembl release 88.
Statistical analysis was performed using R and DESeq2 1.10.1 Bioconductor
library31. The differential expression analysis in DESeq2 uses a generalized linear
model (GLM) where counts are modeled using a negative binomial distribution.
Counts were normalized from the estimated size factors using the median ratio
method and a Wald test was used to test the significance of GLM coefficients.
Alternative splicing analysis was performed by JunctionSeq32 version 1.6.0 and
rMATS33 version 3.2.5. Variants were identified using GATK34 version 3.4-46. At
first, duplicate reads were marked using Picard Tools version 1.122. Reads with N
operators in the CIGAR strings were split into component reads and trimmed to
remove any overhangs into splice junctions. Base quality recalibration and variant
discovery process (HaplotyteCaller) were performed. VCF files were filtrated
according to the clusters having at least three SNPs in a window of 35 bases
between them. Variant annotation was carried out by GATK, SnpEff35, and
SnpSift36.
Small RNA libraries were generated from 2 μg of total RNA using TruSeq Small
RNA Sample Prep Kit (RS-200-0012/0024). The protocol uses RNA molecules that
have a 5ʹ-Phosphate and a 3ʹ-hydroxyl group. RNA adapters were ligated to the
extremity of RNA molecules, in two different steps: the 3ʹ RNA adapter, modified
to specifically target small RNAs including microRNAs, is added before the 5ʹ RNA
adapter. We subsequently performed a reverse transcription followed by
amplification with primers annealing to the adapter ends (30 s at 98 °C; [10 s at
98 °C, 30 s at 60 °C, 15 s at 72 °C] × 13 cycles; 10 min at 72 °C) to selectively enrich
RNA fragments containing adapter molecules on both ends. The last step was an
acrylamide gel purification of 140–145 nt amplified cDNA constructs
(corresponding to cDNA inserts+120 nt adapters). Final libraries were checked for
quality and quantified using capillary electrophoresis. The libraries were sequenced
on Illumina HiSeq 4000 sequencer as single-read 50-base reads following Illumina’s
instructions. Image analysis and base calling were performed using RTA 2.7.3 and
bcl2fastq 2.17.1.14. Adapters were trimmed from total reads with FASTX_Toolkit
[http://hannonlab.cshl.edu/fastx_toolkit/]. Non-coding RNA profiling was
performed by the ncPRO-seq 1.6.5 analysis pipeline37 with the annotation from
miRBase release 2138 and Rfam v11 database36. The DESeq2 package v1.16.131 was
used to normalize and to assess miRNA differential expression between patients
and controls.
Fragment analysis and repeat-primed PCR (RP-PCR). Specific primers
(FAME3-P2F: CCATCAGAGGCAAGCAATGT and FAME3-P1R:
GGAAAAGGGAGGGTTATAGAGGA) were designed to amplify the tandem
repeat region in intron 1 of MARCH6 using primer3 [http://primer3.ut.ee/].
Amplicons were analyzed by polyacrylamide capillary gel electrophoresis on an
ABI 3130xl DNA Analyzer (Applied Biosystems), according to the manufacturer’s
instructions. Fragment sizing was performed using GeneMarker (Softgenetics). The
repeat expansion was amplified by repeat-primed PCR (RP-PCR) with 6-FAM-
labeled FAME3-P2F, P3 (TACGCATCCCAGTTTGAGACG), and either P3-AAA
AT (TACGCATCCCAGTTTGAGACGAATAAAATAAAATAAAATAAAATAA)
or P3-AAATG (TACGCATCCCAGTTTGAGACGAAATGAAATGAAATGAAA
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TG) (5ʹ assays) or 6-FAM-labeled FAME3-P1R, P3 and either P3-TTTCA (TACG
CATCCCAGTTTGAGACG-TTCATTTCATTTCATTTCATTTC) or P3-TTTTA
(TACGCATCCCAGTTTGAGACG-TTTTATTTTATTTTATTTTATTTTATTTT
ATTTTA) primers (3ʹ assays). PCR was performed with 100 ng genomic DNA, 0.8
µM primer FAME3-P2F or FAME3-P1R, 0.8 µM primer P3-PU, and 0.08 µM
primer P3-TTTCA or P3-AAATG or 0.27 µM primer P3-AAAAT or P3-TTTTA
using the HotStarTaq Master Mix (QIAGEN). The PCR program used with the P3-
TTTCA or P3-AAATG primers was 95 °C for 15 min, followed by 40 cycles (94 °C
for 1 min, 58 °C for 1 min, and 72 °C from for 2 min 30 s) and a final extension step
(72 °C for 10 min). The PCR program used with the P3-AAAAT or P3-TTTTA
primers was: 95 °C for 15 min, followed by 40 cycles (94 °C for 1 min, 54 °C for 1
min, and 60 °C from for 2 min 30 s) and a final extension step (60 °C for 10 min).
RP-PCR products were detected on an ABI 3130xl DNA Analyzer and analyzed
using GeneMapper® software v5.0 (Thermo Fisher Scientific).
Sanger sequencing. Sanger sequencing was used to determine the number of
TTTTA repeats present on non-pathogenic alleles in 30 healthy blood donors
(Supplementary Fig. 4a) and FAME3 patients. After amplification of the corre-
sponding region using primers FAME3-P2F and FAME3-P1R, forward and reverse
sequence reactions were performed with the Big Dye Terminator Cycle Sequencing
Ready Reaction Kit (Applied Biosystems) using the same primers. G50-purified
sequence products were run on an ABI 3130xl DNA Analyzer (Applied Biosys-
tems) and sequence data were analyzed with Geneious (Biomatters).
Haplotype analysis. SNP genotypes were available for individuals of Families 1
and 225. A core haplotype was defined based on sharing amongst affected indivi-
duals from both French families. Haplotype dating was performed using a pub-
lished method39, and website developed in the Bahlo lab [https://shiny.wehi.edu.
au/rafehi.h/mutation-dating/]. This method determines the age of the most recent
common ancestor (MRCA) from whom the core haplotype was inherited. This
method can also be used for individuals with shared ‘extended haplotypes’, who are
likely to have a MRCA who is more recent than that for the whole group.
Oxford nanopore sequencing. DNA extraction was done from 5mL fresh blood
samples using a modified salting-out procedure40. Ten micrograms of DNA was
sheared in 100 µL of water by pulling it ten times through a HPLC injection needle
(blunt metal needles [91029] Hamilton, attached to a 1 mL BD Luer Lock syringe)
and cleaned up with 0.4X AMPure XP beads. Approximately 3.5–5 µg of DNA was
used for the library preparation with the 1D Ligation Sequencing Kit (SQK-
LSK108) and sequenced on the GridION sequencer utilizing R9.4.1 flow cells. Base
calling was done using guppy (Oxford Nanopore Technologies), adapters were
trimmed by porechop and reads were filtered with NanoFilt41 for quality >8.
Alignment was done by minimap242 and bam files were generated using sam-
tools43. Structural variants were called using NanoSV44 and picky45. Tandem
repeat lengths within the extracted reads were further analyzed by NanoSatellite46.
Molecular combing (Fiber FISH). Freshly sampled blood cells from nine patients
(1-IV-6, 1-IV-8,1-IV-9, and 1-IV-11 from Family 1, 2-IV-,9 2IV-18, 2-V-9, 2-V-20,
and 2-V-22 from Family 2) and one control individual (healthy blood donor) were
embedded in agarose plugs using the FiberPrep® DNA extraction kit from
Genomic Vision (Bagneux, France). DNA was purified by proteinase K and sar-
kosyl treatment overnight according to manufacturer instructions. Agarose was
melted and digested by an overnight beta-agarase treatment. Purified DNA was
diluted in MES buffer and combed on CombiCoverslips® using a FiberComb®
(both from Genomic Vision), immobilized on the surface by baking at 60 °C for 4 h
and stored at −20 °C until further use. FiberProbes® DNA FISH probes were
designed and labeled by Genomic Vision. Briefly, overlapping probes corre-
sponding to 5ʹ and 3ʹ regions flanking the expansion were amplified by long-range
PCR and purified and used as templates for probe labeling by random priming and
combined to a probe directed against the TTTCA part of the expansion (biotin-
TTTCATTTCATTTCATTTCATTTCATTTCATTTCA). Hybridization was car-
ried out overnight in a Hybridizer (Dako) with the labeled probes, detected using
fluorophore-coupled antibodies layers (BA-0500 Biotinylated Anti-Streptavidin
Antibody, VECTOR Laboratories, dilution 1:25). The entire coverslip was scanned
on a FiberVision® automated scanner (Genomic Vision). Image analysis and sig-
nals measurement was performed using FiberStudio® software (Genomic Vision).
We measured each part of the signals (B: blue, R: red, G: green) for all alleles
present on one coverslip (healthy control and individuals 1-IV-6, 1-IV-9, 1-IV-11,
2IV-18, 2-V-9, 2-V-20, 2-V-22) or two coverslips (individuals 1-IV-8 and 2-IV-9).
For alleles without red staining, the unstained part between the blue and green
signals was referred to as Y on images. For alleles with red staining (pathogenic
alleles), Y refers to the unstained part between the blue and red signals; unstained
parts were also detected between the red and green signals or in-between two red
signals and referred to as W. Distribution of non-pathogenic versus pathogenic
alleles was assessed by comparing data of the control individual to those of affected
patients (Supplementary Fig. 7). Based on the distribution observed in the control,
three categories of alleles without red staining were defined: normal (N) alleles
(Y < 5.5 kb, n= 113 in Ctrl), undefined (U) alleles (5.5 ≤ Y < 8.5, n= 1 in Ctrl) and
likely pathogenic (P) alleles (Y ≥ 8.5, n= 0 in Ctrl) (Supplementary Fig. 7a, c). Only
definite pathogenic (with red staining) and likely pathogenic (without red staining;
Y ≥ 8.5) were included in further calculations of expansion length (Fig. 5a, b,
Supplementary Fig. 8, and Supplementary Table 1). Rearranged and incomplete
alleles were annotated and counted for each patient but excluded from further
calculations. For each pathogenic allele, the total size of the expansion was cal-
culated using the formula: Yp − Yn+ R+W, where Yp is the individual measure of
the allele and Yn is the median Y value of the normal alleles from the same
individual. Allele distributions, calculations (mean, median, and standard devia-
tion), graphs (box plots), and statistical analyses were performed using in-house R
scripts.
Real-time quantitative reverse transcription PCR (qRT-PCR). MARCH6 iso-
forms and their corresponding expression were assessed using Alamut 2.11
(Interactive Biosoftware) and the GTEx database [https://gtexportal.org/home/].
Blood samples from 12 expansion carriers (1-IV-6, 1-IV-9, 1-IV-11, and all nine
expansion carriers from Family 2) and 10 non-carrier individuals were collected in
Paxgene® Blood RNA tubes (PreAnalytiX, Qiagen). Total RNA was isolated using
the PAXgene® Blood RNA Kit (Qiagen) and RNA integrity was verified on a 2100
Bioanalyzer (Agilent). In parallel, fibroblasts from four expansion carriers (1-IV-6,
1-IV-8, 1-IV-9, 1-IV-11) and four unrelated healthy individuals were cultured in
AmnioMAX (Thermo Fisher Scientific), and total RNA was isolated using the
RNeasy mini kit (Qiagen). Primers allowing specific amplification of exons 7–8
(Ex7F-GGAGGAAGATGACGCTGGT, Ex8R-AAAGCATTCCAATTCATGTCA
TC) and exons 14–15 ofMARCH6 (Ex14F-AATTGGAGTATTCCCTCTCATTTG,
Ex14/15R-CAGAGTAGCATCAAACATTTCCA), and primers amplifying intron
1 before (intr1preF2-TGAGGAAACTGATGGTTAGTATGATT, intr1preR2-CTC
TGACAGACATGAGTCTGAATCT) or after the expansion (intr1postF3-TTGTT
GTGAATGGCTGGATG, intr1postR3-AGGTGCGGATCAGTCCTACA) were
designed using the Universal ProbeLibrary Assay Design Center (Roche). Efficiency
of each primer pair was first verified using serial dilutions of cDNA (for exonic
assays spanning introns) or genomic DNA (for intronic assays) of control samples.
To eliminate possible contamination of extracted RNA by genomic DNA, 1 µg of
total RNA of each sample was treated for 30 min at 37 °C with RQ1 RNase-Free
DNase (Promega) before proceeding to reverse transcription. cDNAs were syn-
thesized using the LunaScript RT supermix Kit (New England Biolab). Reverse-
transcribed MARCH6 cDNA was quantified using the LightCycler 480 Probes
Master Mix from Roche and Universal Probe Library specific probes. PPIA (F-AT
GCTGGACCCAACACAAAT, R-TCTTTCACTTTGCCAAACACC) was used as
the control gene. Each sample was run in triplicate on a Lightcycler 480 (Roche)
with the following thermocycling conditions: 95 °C for 10 min (1 cycle); 95 °C for
15 s and 60 °C for 1 min (45 cycles); and 37 °C for 30 s (1 cycle). Relative abun-
dance was calculated using the formula 2ΔΔCt= (CtMARCH6− CtPPIA)individual tested/
mean (CtMARCH6−CtPPIA)control individuals. For blood samples, samples (n= 22)
were run on two different plates each including two MARCH6 specific primer pairs
and PPIA, as well as the same two individuals (one expansion carrier, one non-
carrier) to control for experiment reproducibility between plates. Fibroblasts (n=
8) samples were run on the same plate. Value distributions were compared using a
Wilcoxon–Mann–Whitney rank-sum test (two-sided).
Western blotting. Fibroblast cells (1 × 106) from four expansion carriers of Family
1 (1-IV-6, 1-IV-8, 1-IV-9, 1-IV-11) and four healthy individuals were lysed in 100
µL of NP-40-buffer (500 mM NaCl, 20 mM Tris pH 8, 1 mM EDTA pH 8, 0.5%
NP-40) supplemented with Halt Protease Inhibitor Cocktail (Thermo Fisher).
Proteins were separated on 10% SDS polyacrylamide gels and transferred to
nitrocellulose membrane (GE Healthcare). We used the bs-9340R polyclonal
antibody (Bioss Antibodies, dilution 1:300) to reveal MARCH6 and an anti-β-
Tubulin (#2146, Cell Signaling Technology; dilution 1:1000) as loading control. We
used ImageJ to quantify protein expression.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Families included in this study have not consented to have their genome data publicly
released. The source data underlying Figs. 1, 2b, 3c, 4f, 5a–d and 6b–e, as well as
Supplementary Figs. 4a, 7, 8 and 12a–b are provided as a Source Data file. Raw images
(molecular combing experiments) and raw nanopore data (corresponding to reads
included in this study) are available from the corresponding author, upon request. The
MARCH6 expansion has been deposited in ClinVar under the accession SCV000924549.
RNA-seq and small RNA-seq data have been deposited in the ArrayExpress database at
EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession numbers E-MATB-8300 and
E-MTAB-8301 .
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